Abstract
During pregnancy both mother and foetus are at increased risk of being infected with either pandemic or seasonal influenza viruses, and it is thus legitimate to implement enhanced surveillance for infection particularly with the A/H1N1v and discuss priority vaccine administration. We will review the alterations in immunologic parameters which lead to some degree of cellular immunodeficiency, but also in anatomic changes and pulmonary restrictions which contribute to this suceptibility of pregnant women to severe complications of an influenza infection. We also provide an update on the epidemiological data available for the A/H1N1v infection in this population, and discuss the benefit/risk ratio of treatment with the antiviral medications.
MeSH terms
-
Adolescent
-
Adult
-
Antiviral Agents / adverse effects
-
Antiviral Agents / therapeutic use
-
Disease Outbreaks
-
Disease Susceptibility
-
Female
-
Fetal Death / etiology
-
Fetal Diseases / etiology
-
Humans
-
Immunity, Cellular
-
Immunocompromised Host
-
Infant, Newborn
-
Influenza A Virus, H1N1 Subtype
-
Influenza Vaccines
-
Influenza, Human / drug therapy
-
Influenza, Human / epidemiology*
-
Influenza, Human / etiology
-
Influenza, Human / mortality
-
Influenza, Human / prevention & control
-
Pregnancy
-
Pregnancy Complications, Infectious / epidemiology*
-
Pregnancy Complications, Infectious / immunology
-
Pregnancy Complications, Infectious / mortality
-
Pregnancy Complications, Infectious / prevention & control
-
Young Adult
Substances
-
Antiviral Agents
-
Influenza Vaccines